![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
The top three Prescribed Perspectives articles downloaded by health systems in June.
How Biosimilars Differ from Biologics in Cost and Benefits
Increased affordability of biosimilars may have an impact on healthcare systems.
By
Date
August 01, 2022
By: McKesson Medical Surgical Editorial Team
Read time: 1 minute
An overview of biosimilars and how they compare to biologics
Health systems and clinics considering the adoption of biosimilars for treatment should understand and consider how they compare to biologics. Biosimilar products are therapies that have the same therapeutic value and potency as their biologic counterparts, the use of biosimilar drugs may save money for both patients and providers. Increased affordability of the biosimilars may also have a meaningful impact on the healthcare system.
To learn more, read What are biosimilars? How biosimilars differ from biologics in cost & benefits.
Subscribe Now
To learn how McKesson can help health systems achieve more, sign up to have the Prescribed Perspectives newsletter delivered directly to your inbox.
Related Stories
This visual helps illustrate the nuances of each type of bagging in specialty pharmacy and what it may mean for your health system.
As strategic partners, our Specialty Pharmacy Enablement experts can help drive improvements across the board.
In a unique, retreat-style setting, health systems leaders had close conversations around best practices, wins, struggles, and solutions.
Discover three key takeaways from a recent C-suite roundtable discussing the benefits and challenges of central fill for health systems.
Industry event highlights how connection, creativity, and a fresh perspective are shaping the future of health system innovation.
The top three Prescribed Perspectives articles downloaded by health systems in April.
An exclusive introduction to our newest services and solutions designed to help forward-thinking health systems modernize their specialty and infusion strategies.
As the infusion services market continues to evolve and challenge one of health systems’ longstanding service lines – new opportunities are also emerging.
Drug shortages have decreased, but supply chain complexity requires ongoing innovation and resilience to maintain drug availability.